XML 42 R27.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

12 Months Ended

Dec. 31, 2021

Revenue by payor class as a percentage of total net service revenue is as follows:


	As of December 31,
	2021		2020		2019
Home Health:
Medicare	41	%	41	%	44	%
Non-Medicare - Episodic-based	8	%	7	%	9	%
Non-Medicare - Non-episodic based	12	%	13	%	12	%
Hospice (1):
Medicare	34	%	34	%	30	%
Non-Medicare	2	%	2	%	1	%
Personal Care	3	%	3	%	4	%
High Acuity Care (2)	—	%	—	%	—	%
	100	%	100	%	100	%

(1) Acquired Compassionate Care Hospice on February 1, 2019, RoseRock Healthcare on April 1, 2019, Asana Hospice on January 1, 2020 and AseraCare Hospice on June 1, 2020.

(2) Acquired Contessa Health on August 1, 2021.

Schedule of Cash Cash Equivalents and Restricted Cash

The following table summarizes the balances related to our cash, cash equivalents and restricted cash (amounts in millions):


	As of December 31,
	2021		2020
Cash and cash equivalents	$	42.7	$	81.8
Restricted cash	3.1		1.5
Cash, cash equivalents and restricted cash	$	45.8	$	83.3

Schedule of Estimated Useful Lives of Property and Equipment

We generally provide for depreciation over the following estimated useful service lives.


			Years
Building			39
Leasehold improvements			Lesser of lease term or expected useful life
Equipment and furniture			3 to 7
Vehicles			5
Computer software			2 to 7
Finance leases			3

Schedule of Property and Equipment

The following table summarizes the balances related to our property and equipment for 2021 and 2020 (amounts in millions):


	As of December 31,
	2021		2020
Building and leasehold improvements	$	9.1	$	9.0
Equipment and furniture	54.7		53.1
Finance leases	4.5		5.9
Computer software	47.0		50.7
	115.3		118.7
Less: accumulated depreciation	(96.9)		(95.0)
	$	18.4	$	23.7

Schedule of Fair Value of Financial Instruments

The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):


			Fair Value at Reporting Date Using
Financial Instrument	Carrying Value as of December 31, 2021		Quoted Prices in Active Markets for Identical Items (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Long-term obligations	$	448.0	$	—	$	474.9	$	—

Schedule of Weighted-Average Shares Outstanding

The following table sets forth, for the periods indicated, shares used in our computation of weighted-average shares outstanding, which are used to calculate our basic and diluted net income attributable to Amedisys, Inc. common stockholders (amounts in thousands):


	For the Years Ended December 31,
	2021	2020	2019
Weighted average number of shares outstanding – basic	32,642	32,559	32,142
Effect of dilutive securities:
Stock options	122	420	545
Non-vested stock and stock units	208	289	303
Weighted average number of shares outstanding – diluted	32,972	33,268	32,990
Anti-dilutive securities	114	25	117